Lung Bacteriobiota and Influenza Mortality

Study Overview
=================
Brief Summary
-----------------
Influenza is a potentially lethal disease still responsible for thousands excess deaths both in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. Lung microbiota has been shown to be involved in the immunity against influenza and is correlated with lung inflammation in numerous chronic respiratory diseases. We therefore aim to analyse the correlation between lung bacteriobiota and influenza ICU mortality

Detailed Description
-----------------
Influenza is a viral disease which is still responsible for thousands of excess deaths par year both in Europe and in the US. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. As lung microbiota is correlated with lung inflammation in numerous chronic respiratory diseases, we hypothesize that lung microbiota would be correlated with influenza outcomes. In a pilot study, we found that lung bacteriobiota but not mycobiota is associated with influenza ICU mortality. We therefore aim to confirm this correlation between lung bacteriobiota and influenza mortality.

Official Title
-----------------
Association of Lung Bacteriobiota With Intensive Care Unit Mortality in ARDS Patients: MicroFlu Study

Conditions
-----------------
Influenza, Critical Illness

Intervention / Treatment
-----------------
* Diagnostic Test: influenza screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient above 18 year-old admitted to intensive care unit Influenza diagnosis by PCR or rapid diagnostic test Exclusion Criteria: Guardianship or curatorship Prisoners No health insurance No legal representative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: influenza screening|positive influenza screening|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung bacteriobiota and ICU mortality | Comparison of lung bacteriobiota alpha diversity between influenza ICU survivors and non-survivors | at admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung bacteriobiota and ICU mortality | Analysis of lung bacteriobiota beta diversity between influenza ICU survivors and non-survivors | at admission | 
| Lung bacteriobiota and 7-day mortality | Analysis of lung bacteriobiota beta diversity between influenza 7-day survivors and non-survivors | at admission | 
| Bacteria and ICU mortality | Association of bacteria with influenza ICU mortality by LefSe method | at admission | 
| Bacteria and 7-day mortality | Association of bacteria with influenza 7-day mortality by LefSe method | at admission | 
| ICU mortality based on Shannon index | Comparison of ICU mortality based on a threshold of 1.79 for Shannon Index | at admission | 
| Lung bacteriobiota and 7-day mortality | Comparison of lung bacteriobiota alpha diversity between influenza 7-day survivors and non-survivors | at admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
influenza, microbiota, intensive care unit